CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 39 enrolled
Drug / intervention
G-CSF +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00906945
NCT00906945Phase 2Completed
CompareCT.gov

Chemosensitization With Plerixafor Plus G-CSF in Relapsed or Refractory Acute Myeloid Leukemia

Washington University School of Medicine·interventional·Posted May 21, 2009·Updated Apr 4, 2017

In Brief

A Phase 2 clinical trial evaluating G-CSF, Plerixafor, and 3 other interventions for Leukemia, Myeloid, Acute. Completed, enrolled 39 participants across 3 sites.

Detailed Summary

This study is designed to test the combination of Plerixafor with G-CSF for chemosensitization in patients with relapsed or refractory AML.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Myeloid, Acute
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 21, 2009
Enrollment StartFeb 1, 2011
Primary CompletionNov 1, 2012
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.1 years ago

Interventions

G-CSFdrug

Plerixafordrug

Mitoxantronedrug

Etoposidedrug

Cytarabinedrug